Genome-wide identification and characterization of novel factors conferring resistance to topoisomerase II poisons in cancer

Cancer Research

Volumn 75, Issue 19, 2015, Pages 4176-4187

  Wijdeven, Ruud H ^a   Pang, Baoxu ^a,b   Van Der Zanden, Sabina Y ^a   Qiao, Xiaohang ^a   Blomen, Vincent ^a   Hoogstraat, Marlous ^a   Lips, Esther H ^a   Janssen, Lennert ^a   Wessels, Lodewyk ^a   Brummelkamp, Thijn R ^a   Neefjes, Jacques ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; COMPLEMENTARY DNA; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE (ATP HYDROLYSING); DOCETAXEL; DOXORUBICIN; ETOPOSIDE; KELCH LIKE ECH ASSOCIATED PROTEIN 1; PROTEIN C9ORF82; PROTEIN SWI; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR SNF; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; APOPTOSIS REGULATORY PROTEIN; C9ORF82 PROTEIN, HUMAN; DNA BINDING PROTEIN; DNA HELICASE; GYRASE INHIBITOR; KEAP1 PROTEIN, HUMAN; NONHISTONE PROTEIN; NUCLEAR PROTEIN; SIGNAL PEPTIDE; SMARCA4 PROTEIN, HUMAN; SMARCB1 PROTEIN, HUMAN; TAXOID; TOPOTECAN; TUMOR PROTEIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CELL PROLIFERATION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DNA DAMAGE; DNA END JOINING REPAIR; DNA SYNTHESIS; DOUBLE STRANDED DNA BREAK; DRUG SENSITIVITY; FLOW CYTOMETRY; GEL ELECTROPHORESIS; GENE DELETION; GENE EXPRESSION; GENE MUTATION; GENETIC SCREENING; GENETIC TRANSFECTION; HAPLOIDY; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; NULL ALLELE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRIPLE NEGATIVE BREAST CANCER; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; CARCINOMA; CRISPR CAS SYSTEM; DRUG RESISTANCE; FEMALE; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION; GENETICS; METABOLISM; PATHOLOGY; PHYSIOLOGY; RNA INTERFERENCE; SARCOMA; TRIPLE NEGATIVE BREAST NEOPLASMS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS REGULATORY PROTEINS; CAPECITABINE; CARCINOMA; CHROMOSOMAL PROTEINS, NON-HISTONE; CRISPR-CAS SYSTEMS; CYCLOPHOSPHAMIDE; DNA HELICASES; DNA-BINDING PROTEINS; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; ETOPOSIDE; FEMALE; GENE EXPRESSION PROFILING; GENOME-WIDE ASSOCIATION STUDY; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; NEOPLASM PROTEINS; NUCLEAR PROTEINS; RNA INTERFERENCE; RNA, SMALL INTERFERING; SARCOMA; TAXOIDS; TOPOISOMERASE II INHIBITORS; TOPOTECAN; TRANSCRIPTION FACTORS; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84945590157     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-15-0380     Document Type: Article

References (49)

1. Pommier Y. Drugging topoisomerases: lessons and challenges. ACS Chem Biol 2013;8:82-95.
2. Borst P. Cancer drug pan-resistance: pumps, cancer stem cells, quiescence, epithelial to mesenchymal transition, blocked cell death pathways, persisters or what? Open Biol 2012;2:120066.
3. Pang B, Qiao X, Janssen L, Velds A, Groothuis T, Kerkhoven R, et al. Drug-induced histone eviction from open chromatin contributes to the chemotherapeutic effects of doxorubicin. Nat Commun 2013;4: 1908.
4. Yang F, Kemp Christopher Â.J, Henikoff S. Doxorubicin enhances nucleosome turnover around promoters. Curr Biol 2013;23:782-87.
5. Pang B, de Jong J, Qiao X, Wessels LF, Neefjes J. Chemical profiling of the genome with anti-cancer drugs defines target specificities. Nat Chem Biol 2015;11:472-80.
6. Callaghan R, Luk F, Bebawy M. Inhibition of the multidrug resistance Pglycoprotein: time for a change of strategy? Drug Metab Dispos 2014;42: 623-31.
7. Burgess DJ, Doles J, Zender L, Xue W, Ma B, McCombie WR, et al. Topoisomerase levels determine chemotherapy response in vitro and in vivo. Proc Natl Acad Sci U S A 2008;105:9053-8.
8. Bouwman P, Jonkers J. The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance. Nat Rev Cancer 2012; 12:587-98.
9. Zoppoli G, Regairaz M, Leo E, Reinhold WC, Varma S, Ballestrero A, et al. Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents. Proc Natl Acad Sci USA 2012; 109:15030-5.
10. Carette JE, Guimaraes CP, Wuethrich I, Blomen VA, Varadarajan M, Sun C, et al. Global gene disruption in human cells to assign genes to phenotypes by deep sequencing. Nat Biotechnol 2011;29:542-6.
11. Shibata T, Kokubu A, Gotoh M, Ojima H, Ohta T, Yamamoto M, et al. Genetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to chemotherapy in gallbladder cancer. Gastroenterology 2008; 135:1358-68, 68.e1-4.
12. Singh A, Misra V, Thimmulappa RK, Lee H, Ames S, Hoque MO, et al. Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer. PLoS Med 2006;3:e420.
13. Network CGAR. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008;455:1061-8.
14. Kadoch C, Hargreaves DC, Hodges C, Elias L, Ho L, Ranish J, et al. Proteomic and bioinformatic analysis ofmammalian SWI/SNF complexes identifies extensive roles in human malignancy. Nat Genet 2013;45: 592-601.
15. Carette JE, Raaben M, Wong AC, Herbert AS, Obernosterer G, Mulherkar N, et al. Ebola virus entry requires the cholesterol transporter Niemann-Pick C1. Nature 2011;477:340-3.
16. Johnson JP, Demmer-Dieckmann M, Meo T, Hadam MR, Riethmuller G. Surface antigens of human melanoma cells defined by monoclonal antibodies. I. Biochemical characterization of two antigens found on cell lines and fresh tumors of diverse tissue origin. Eur J Immunol 1981;11:825-31.
17. Hsu PD, Scott DA, Weinstein JA, Ran FA, Konermann S, Agarwala V, et al. DNA targeting specificity of RNA-guided Cas9 nucleases. Nat Biotechnol 2013;31:827-32.
18. Wang H, Yang H, Shivalila CS, Dawlaty MM, Cheng AW, Zhang F, et al. One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering. Cell 2013;153:910-8.
19. Auer TO, Duroure K, De Cian A, Concordet JP, Del Bene F. Highly efficient CRISPR/Cas9-mediated knock-in in zebrafish by homology-independent DNA repair. Genome Res 2014;24:142-53.
20. Neijenhuis S, Verwijs-Janssen M, Kasten-Pisula U, Rumping G, Borgmann K, Dikomey E, et al. Mechanism of cell killing after ionizing radiation by a dominant negative DNA polymerase beta. DNA Repair 2009;8:336-46.
21. Paul P, van den Hoorn T, Jongsma ML, Bakker MJ, Hengeveld R, Janssen L, et al. A Genome-wide multidimensional RNAi screen reveals pathways controlling MHC class II antigen presentation. Cell 2011;145:268-83.
22. de Ronde JJ, Lips EH, Mulder L, Vincent AD, Wesseling J, Nieuwland M, et al. SERPINA6, BEX1, AGTR1, SLC26A3, and LAPTM4B are markers of resistance to neoadjuvant chemotherapy in HER2-negative breast cancer. Breast Cancer Res Treat 2013;137:213-23.
23. Trapnell C, Pachter L, Salzberg SL. Top Hat: discovering splice junctions with RNA-Seq. Bioinformatics 2009;25:1105-11.
24. Anders S, Pyl PT, Huber W. HTSeq-a Python framework to work with highthroughput sequencing data. Bioinformatics 2015;31:166-9.
25. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-Seq data with DESeq2. Genome Biol 2014;15:550.
26. Benjamin RS, Riggs CE, Bachur NR. Plasma pharmacokinetics of adriamycin and its metabolites in humans with normal hepatic and renal function. Cancer Res 1977;37:1416-20.
27. Ohta T, Iijima K, Miyamoto M, Nakahara I, Tanaka H, Ohtsuji M, et al. Loss of Keap1 function activates Nrf2 and provides advantages for lung cancer cell growth. Cancer Res 2008;68:1303-9.
28. Wang XJ, Sun Z, Villeneuve NF, Zhang S, Zhao F, Li Y, et al. Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2. Carcinogenesis 2008;29:1235-43.
29. Hohmann AF, Vakoc CR. A rationale to target the SWI/SNF complex for cancer therapy. Trends Genet 2014;30:356-63.
30. Tsang WP, Chau SP, Kong SK, Fung KP, Kwok TT. Reactive oxygen species mediate doxorubicin induced p53-independent apoptosis. Life Sci 2003; 73:2047-58.
31. Rogalska A, Koceva-Chyla A, Jozwiak Z. Aclarubicin-induced ROS generation and collapse of mitochondrial membrane potential in human cancer cell lines. Chem Biol Interact 2008;176:58-70.
32. Konstantinopoulos PA, Spentzos D, Fountzilas E, Francoeur N, Sanisetty S, Grammatikos AP, et al. Keap1 mutations and Nrf2 pathway activation in epithelial ovarian cancer. Cancer Res 2011;71:5081-9.
33. Sporn MB, Liby KT. NRF2 and cancer: the good, the bad and the importance of context. Nat Rev Cancer 2012;12:564-71.
34. Miyoshi Y, Kurosumi M, Kurebayashi J, Matsuura N, Takahashi M, Tokunaga E, et al. Predictive factors for anthracycline-based chemotherapy for human breast cancer. Breast Cancer 2010;17:103-9.
35. Sinha BK, Haim N, Dusre L, Kerrigan D, Pommier Y. DNA strand breaks produced by etoposide (VP-16,213) in sensitive and resistant human breast tumor cells: implications for the mechanism of action. Cancer Res 1988;48:5096-100.
36. Zhang Y, Johansson E, Miller ML, Janicke RU, Ferguson DJ, Plas D, et al. Identification of a conserved anti-apoptotic protein that modulates the mitochondrial apoptosis pathway. PLoS ONE 2011;6:e25284.
37. Dykhuizen EC, Hargreaves DC, Miller EL, Cui K, Korshunov A, Kool M, et al. BAF complexes facilitate decatenation of DNA by topoisomerase IIalpha. Nature 2013;497:624-7.
38. Hornick JL, Dal Cin P, Fletcher CD. Loss of INI1 expression is characteristic of both conventional and proximal-type epithelioid sarcoma. Am J Surg Pathol 2009;33:542-50.
39. Gasparini P, Facchinetti F, Boeri M, Lorenzetto E, Livio A, Gronchi A, et al. Prognostic determinants in epithelioid sarcoma. Eur J Cancer 2011;47: 287-95.
40. Lee DF, Kuo HP, Liu M, Chou CK, Xia W, Du Y, et al. KEAP1 E3 ligasemediated downregulation of NF-kappaB signaling by targeting IKKbeta. Mol Cell 2009;36:131-40.
41. Fan W, Tang Z, Chen D, Moughon D, Ding X, Chen S, et al. Keap1 facilitates p62-mediated ubiquitin aggregate clearance via autophagy. Autophagy 2010;6:614-21.
42. Zhan L, Zhang H, Zhang Q, Woods CG, Chen Y, Xue P, et al. Regulatory role of KEAP1 and NRF2 in PPARgamma expression and chemoresistance in human non-small-cell lung carcinoma cells. Free Radic Biol Med 2012; 53:758-68.
43. Lawrence MS, Stojanov P, Mermel CH, Robinson JT, Garraway LA, Golub TR, et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 2014;505:495-501.
44. Barbano R, Muscarella LA, Pasculli B, Valori VM, Fontana A, Coco M, et al. Aberrant Keap1 methylation in breast cancer and association with clinicopathological features. Epigenetics 2013;8:105-12.
45. Quennet V, Beucher A, Barton O, Takeda S, Lobrich M. CtIP and MRN promote non-homologous end-joining of etoposide-induced DNA double-strand breaks in G1. Nucleic Acids Res 2011;39:2144-52.
46. Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR, et al. The somatic genomic landscape of glioblastoma. Cell 2013;155: 462-77.
47. Versteege I, Sevenet N, Lange J, Rousseau-Merck MF, Ambros P, Handgretinger R, et al. Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. Nature 1998;394:203-6.
48. Margol AS, Judkins AR. Pathology and diagnosis of SMARCB1-deficient tumors. Cancer Genet 2014;207:358-64.
49. Tomlinson GE, Breslow NE, Dome J, Guthrie KA, Norkool P, Li S, et al. Rhabdoid tumor of the kidney in the National Wilms' Tumor Study: age at diagnosis as a prognostic factor. J Clin Oncol 2005;23: 7641-5.